Braveheart Bio (BRVE) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Braveheart Bio is the larger company by market cap ($1.67 billion vs $1.59 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | OCUL |
|---|---|---|
| Share price | $18.58 | $7.23 |
| Market cap | $1.67B | $1.59B |
| 1-day change | -6.11% | -1.50% |
| YTD return | — | -40.44% |
| 1-year return | — | -37.24% |
| 5-year return | — | -35.39% |
| EPS (TTM) | $-5.70 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $16.44 |
| 52-week low | $18.47 | $6.23 |
| Distance from 52-week high | -41.94% | -56.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.54% | +274.69% |
| Average volume | 567.47K | 2.78M |
| Shares outstanding | 90.04M | 219.62M |
| Employees | 49 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
BRVE vs OCUL FAQ
Which is bigger, Braveheart Bio or Ocular Therapeutix?
Braveheart Bio (BRVE) is larger, with a market capitalization of $1.67B compared with $1.59B for Ocular Therapeutix (OCUL).
Are Braveheart Bio and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.